Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well trametinib with or without Akt inhibitor
GSK2141795 (GSK2141795) works in treating patients with uveal melanoma that has spread to
other parts of the body (metastatic). Trametinib and GSK2141795 may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. It is not yet known whether
trametinib is more effective with or without GSK2141795 in treating patients with metastatic
uveal melanoma.